CD274 and neoplasm: Additionally, the study assessed PD-L1 expression in 59 patients, revealing that patients with a PD-L1 Tumor Proportion Score (TPS) ≥ 1 had a higher survival benefit compared to those with PD-L1 TPS < 1 (ORR: 28.6% vs 9.6%; Disease Control Rate (DCR): 85.7% vs 38.5%; median PFS: 7.4 months vs 1.9 months; median OS: 15.2 months vs 8.0 months).